Patients who have had a stroke can ward off the risk of pneumonia with angiotensin-converting enzyme (ACE) inhibitors. For the study, the researchers evaluated the risk of pneumonia in >1000 patients who had had a stroke. The patients involved in the 35-month study were given 1 of 3 treatments: ACE inhibitors, other blood pressure drugs, or a placebo. The data showed 2.8% of the ACE inhibitor group developed pneumonia, compared with 8.5% of the patients in the other 2 groups. (The findings were reported in Neurology, February 9, 2005.)
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs